Skip to main content

Table 1 Baseline characteristics

From: Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

 

M2698 monotherapy (N = 62)

M2698/trastuzumab (N = 13)

M2698/tamoxifen (N = 26)

Age (years)

< 65

45 (72.6)

9 (69.2)

18 (69.2)

65–74

12 (19.4)

3 (23.1)

4 (15.4)

75–84

5 (8.1)

1 (7.7)

4 (15.4)

Male/female

21/41 (33.9/66.1)

0/13 (0/100)

0/26 (0/100)

ECOG PS: 0/1

20/42 (32.3/67.7)

3/10 (23.1/76.9)

13/13 (50/50)

No. of prior lines of anticancer therapy: 1/2/3/4/ ≥ 5

57/47/31/21/16 (91.9/75.8/50.0/33.9/25.8)

13/12/12/11/9 (100/92.3/92.3/84.6/69.2)

25/22/23/19/19 (96.2/84.6/88.5/73.1/73.1)

Prior therapies

Chemotherapy

55 (88.7)

13 (100)

22 (84.6)

Antibody therapy

6 (9.7)

3 (23.1)

3 (11.5)

Kinase inhibitor

4 (6.5)

1 (7.7)

7 (26.9)

Hormonal

10 (16.1)

5 (38.5)

19 (73.1)

Other

8 (12.9)

2 (15.4)

5 (19.2)

Primary tumor

Colon

5 (8.1)

0

0

Rectum

1 (1.6)

0

0

Breasta

8 (12.9)

13 (100)

24 (92.3)

Pancreas

2 (3.2)

0

0

Lung

4 (6.5)

0

0

Endometrium

5 (8.1)

0

0

Salivary gland

6 (9.7)

0

0

Other

31 (50.0)

0

2 (7.7)

Tumor molecular alterationsb

AKT1

3 (4.8)

0

6 (23.1)

AKT2

2 (3.2)

0

0

AKT3

2 (3.2)

0

1 (3.8)

PTEN

13 (21.0)

0

3 (11.5)

PIK3CA

32 (51.6)

8 (61.5)

15 (57.7)

EGFR

3 (4.8)

0

1 (3.8)

KRAS

4 (6.5)

0

0

ER + 

3 (4.8)

9 (69.2)

21 (80.8)

PR + 

3 (4.8)

9 (69.2)

20 (76.9)

HER 1 +/2 +/3 +

1/2/0 (1.6/3.2/0)

2/3/7 (15.4/23.1/53.8)

5/3/1 (19.2/11.5/3.8)

  1. ECOG PS Eastern Cooperative Oncology Group Performance Status, N number of patients
  2. Data show the number of patients (percent)
  3. aPatients with triple-negative breast cancer were included in the study
  4. bTumor molecular profiles were not available for all patients